---
document_datetime: 2025-11-25 10:58:07
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/skyrizi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: skyrizi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.0987818
conversion_datetime: 2025-12-19 04:57:36.908703
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Skyrizi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 14/10/2025                          |                                             | PL                               |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000296296                     | PRODUCTS - C.I.z Other variation - Accepted To update section 7 'Instructions for Use' for the On-body Delivery System (OBDS) of the Risankizumab 180 mg/1.2 ml and 360 mg/2.4 ml solution for injection in cartridge in the package leaflet.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |          |                                                                                                                                                                                                       |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000269736 | This was an application for a group of variations. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.e The change relates to a biological active substance or a starting material/reagent/intermediate used in the manufacture of a biological/immunological product - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control | 02/10/2025 | Annex II | The Annex II has been updated to add AbbVie Operations Singapore PTE Ltd, 23 Tuas South Avenue 6, Singapore, 637022 (ABS) as an alternative site responsible for manufacture of the active substance. |

<div style=\"page-break-after: always\"></div>

|                                       | quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted   |            |      |                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000269665 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 5.1 of the SmPC in order                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 25/09/2025 | SmPC | The efficacy and safety of risankizumab was assessed in a multicenter, randomised, double- blind, placebo-controlled study (UNLIMMITED) that enrolled subjects 18 years of age and older with moderate to severe scalp psoriasis (UNLIMMITED- S), defined as Psoriasis Scalp Severity Index (PSSI) ≥12, scalp Investigator Global Assessment (scalp IGA) ≥3, and ≥30% of the scalp affected, or |

<div style=\"page-break-after: always\"></div>

| to update efficacy and safety information based on interim results from stud M23-702 (UNLIMMITED); this is a phase 4 multicenter, randomized, double-blind study of risankizumab for the treatment of adult subjects with moderate to severe genital psoriasis (UNLIMMITED-G) or moderate to severe scalp psoriasis (UNLIMMITED-S).   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |     | biologic systemic therapy, and 25.7% had received prior biologic therapy. The primary endpoint (sPGA- G of 0 or 1) and key secondary endpoints sPGA-G of 0, DLQI of 0 or 1, GPI- NRS reduction of ≥4 -point from baseline, GenPs-SFQ item 2 score of 0 (never) or 1 (rarely)) at Week 16 were met. The safety profile of risankizumab in studies UNLIMMITED-S and UNLIMMITED-G was consistent with the safety profile observed in previous studies of patients with plaque psoriasis. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000293212 | B.I ACTIVE SUBSTANCE - B.I.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 29/08/2025 | N/A |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Variation type IB / EMA/VR/0000261926 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z (IB) - To reclassify serious hypersensitivity reactions from an important potential risk to an important identified risk. The MAH also took the opportunity to amended Studies P23-654 and P23-653 protocols to add the ulcerative colitis study population to the approved Crohn's disease studies that are currently under review and the due dates for KEEPsAKE 1 was updated | 11/06/2025 | N/A | To reclassify serious hypersensitivity reactions from an important potential risk to an important identified risk. The MAH also took the opportunity to amended Studies P23-654 and P23-653 protocols to add the ulcerative colitis study population to the approved Crohn's disease studies that are currently under review and the due dates for KEEPsAKE 1 was updated from Q3 2025 to Q1 2027 and KEEPsAKE 2 was updated from Q3 2025 to Q4 2026.                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                            | from Q3 2025 to Q1 2027 and KEEPsAKE 2 was updated from Q3 2025 to Q4 2026.   |             |
|----------------------------|-------------------------------------------------------------------------------|-------------|
| PSUR / EMA/PSUR/0000282229 | - -                                                                           | Maintenance |